Albany, NY -- (SBWIRE) -- 11/04/2016 -- The rise in incidences of organ failure in kidney, liver and heart patients across the globe is augmenting the demand for organ transplant procedures.This has further led to rise in the demand for organ preservation solutions that help maintain the organs' viability from the time of donation to transplantation. Market growth for organ preservation solutions will also be propelled by the rise in the number of elderly people worldwide since, risk of organ failure in people of this age group is higher. Also, the American Society of Nephrology states that an aged patient's body shows less graft rejection and that has led to increased preference for organ transplants by surgeons for them. According to the U.S. Department of Health and Human Services, in 2011, 60% of the total number of individuals who underwent organ transplantation procedures in the U.S. were beyond 50 years of age. The global market for organ preservation solutions is expected to grow at a CAGR of 16.5% from 2013 to 2019 to reach an estimated value of USD 0.20 billion in 2019.

The growth of this market will also be driven by the launch of technologically advanced products such as Lifor. Lifor is manufactured by Lifeblood Medical, Inc. and is currently utilized for research purposes only. It is also termed as a blood surrogate and once its effectiveness is clinically proven for preserving human and veterinary organs, the market for the same will grow significantly. Both the developed and developing countries have recorded growth in per capita healthcare expenditure which would provide people with less expensive and better healthcare services. This will also enable the patients to afford organ transplant procedures and hence the organ preservation solutions market will grow. However, growth of this market may get hampered due to high cost of transplantation procedures and lack of organ donors which may shift the preferences of surgeons towards artificial organs.

Get PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1786

The market for Custodiol, accounted for the largest share in terms of revenue of total organ preservation solutions market in 2012 and during the forecast period, is expected to grow at the highest CAGR. This growth will be due to the fact that it can be utilized to preserve various organs such as kidney, lungs, liver and pancreas. Also, it is a vintage preservation solution and hence has gained considerable popularity in the industry which has resulted in increasing preference for Custodiol over other solutions in the market. For instance, Custodiol is utilized extensively for preserving kidneys according to the U.S. National Institute of Health (NIH) journal.

Various type of techniques are used for preserving organs such as hypothermic perfusion preservation (HPP) and static cold storage (SCS). Currently, SCS is the most extensively utilized technique for preservation since it is cheaper than HPP and is more user friendly for physicians. However, with the increasing demand for organs and less number of organ donors, the HPP market is expected to foresee the highest growth since it is capable of preserving organs for longer duration of time with higher accuracy.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1786

Geographically, the European market accounted for the largest share in terms of revenue in 2012 and is expected to grow at the highest CAGR during the forecast period. Various countries of the region like Spain follow opt out policy where a person, if has not opted for denial of organ donation, will be considered as an organ donor after death (brain death) automatically. This increases the number of donors in the region and hence will drive the growth of the market. The total number of deceased donors in the European region amounted to 9,604 in 2011 which was 9,152 in 2009.

The major players operating in the global organ preservation solutions market include Dr. Franz Köhler Chemie GmbH, Bristol-Myers Squibb, XVIVO Perfusion AB, Teva Pharmaceutical Industries Ltd., BioLife Solutions, Inc. and ToleroTech, Inc. These companies strive to maintain their leading position in the market by adopting various business strategies such as launch of innovative products and acquiring various competitors. For instance, Teva Pharmaceutical Industries Ltd. when acquired Barr Pharmaceuticals Ltd., added the leading product Custodiol in its product portfolio.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/